Updates are available Correction dated 2023-05-08

Article History

Received: 7 September 2022

Accepted: 22 March 2023

First Online: 5 April 2023

Change Date: 8 May 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00262-023-03456-w

Declarations

:

: BCÖ received institutional honoraria for lectures and advisory boards from Bristol-Myers Squibb, MSD, Merck, Ipsen, Roche, Pfizer, Novartis, Janssen. GST received research funding from Bayer, consulting fee from Advanz Pharma and travel/accommodation support from Alnylam and Gilead. RH received speaker/advisor honoraria from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol-Myers Squibb, Teva/Mepha and Almirall and research grants from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol-Myers Squibb. AS received speaker honoraria and/or travel compensation for activities with Bristol-Myers Squibb, CSL Behring, Novartis, and Roche, and research support by the Baasch-Medicus Foundation, the Medical Faculty of the University of Bern and the Swiss MS Society, not related to this work.LC received research/non-financial support, advisory fee and stock ownership from Gilead Sciences, F. Hoffmann-La Roche, Novartis, Pfizer, Bristol-Myers Squibb, Sanofi. SIR received consulting or advisory fees from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Eisai, Roche, Novartis, Merck Serono, MSD Oncology, Pfizer, Takeda, AbbVie, research funding from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Eisai, Merck Serono, AbbVie, fees for expert testimony from Roche, AstraZeneca, Bristol-Myers Squibb, and travel/accommodation expenses from Roche Pharma AG, Lilly, Bristol-Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Amgen. All other authors have no relevant financial or non-financial interest to disclose.